Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in Nano-Emulsion Intranasal Delivery Systems for Neurotherapeutics like Depression.

Drug metabolism and bioanalysis·2026
Same author

Cardiomyopathy-Associated Mutations in a Hotspot Region at the C-Terminal Part of Desmin Coil-2 Domain Impair the Intermediate Filament Assembly.

Circulation. Genomic and precision medicine·2026
Same author

Exclusively Chemoselective <i>S</i>‑Acylation for Peptide Radiolabeling Using [<sup>18</sup>F]Fluoronicotinic Acid 4‑Nitrophenyl Ester as a Prosthetic Compound.

ACS omega·2026
Same author

Intracranial Human BT12 Glioblastoma Xenograft is [<sup>18</sup>F]FET PET Negative but 6-[<sup>18</sup>F]Fluoronicotinic Acid PET Positive: Exploring a Novel Approach for Clinical Glioblastoma Imaging.

Molecular pharmaceutics·2026
Same author

ASO Visual Abstract: Enhanced Recovery After Liver Surgery: Does Compliance Impact Survival?

Annals of surgical oncology·2026
Same author

Co-occurrence patterns of malnutrition indicators among children in sub-Saharan Africa.

Communications medicine·2026

Related Experiment Video

Updated: Sep 30, 2025

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.9K

Bivalent EGFR-Targeting DARPin-MMAE Conjugates.

Lennard Karsten1, Nils Janson2, Vadim Le Joncour3

  • 1Cellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, 33615 Bielefeld, Germany.

International Journal of Molecular Sciences
|March 10, 2022
PubMed
Summary

Protein-drug conjugates targeting epidermal growth factor receptor (EGFR) showed sub-nanomolar cytotoxicity in vitro. In vivo, bivalent DARPins demonstrated tumor targeting, but neither conjugate exhibited significant anti-tumor efficacy.

Keywords:
DARPinEGFRKnoevenagel ligationMMAE conjugatesSCC modelantibody-drug conjugatescytotoxicityformylglycine-generating enzymein vivo imagingxenograft

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Experiment Videos

Last Updated: Sep 30, 2025

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.9K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Area of Science:

  • Bioconjugation Chemistry
  • Cancer Therapeutics
  • Molecular Imaging

Background:

  • Epidermal growth factor receptor (EGFR) is a key target in various cancers, including squamous cell carcinoma (SCC) and gliomas.
  • Protein-drug conjugates offer a targeted approach to cancer therapy by delivering cytotoxic agents specifically to tumor cells.
  • Designed Ankyrin Repeat Proteins (DARPins) are emerging as versatile scaffolds for targeted drug delivery due to their small size and high affinity.

Purpose of the Study:

  • To construct and evaluate novel protein-drug conjugates based on anti-EGFR DARPins for cancer therapy.
  • To compare the efficacy of bivalent DARPin dimer (DD1) and DARPin-Fc (DFc) conjugates against monomeric DARPin (DM) and antibody-derived scFv425-Fc (scFvFc).
  • To assess the in vitro cytotoxicity and in vivo tumor targeting and efficacy of these conjugates.

Main Methods:

  • A modular conjugation system utilizing bio-orthogonal protein-aldehyde generation via formylglycine-generating enzyme (FGE).
  • Bifunctional linkers employed tandem Knoevenagel reaction and strain-promoted azide-alkyne cycloaddition (SPAAC) for conjugation.
  • Preparation of DD1-MMAE and DFc-MMAE conjugates with monomethyl auristatin E (MMAE) as the toxin.

Main Results:

  • DD1-MMAE and DFc-MMAE conjugates exhibited sub-nanomolar cytotoxicity against A431 cells in vitro.
  • In vivo imaging revealed specific tumor targeting for DD1 and scFvFc, but not for DFc, due to unspecific binding of bivalent DARPins to ubiquitously expressed EGFR.
  • No significant anti-tumor efficacy was observed in vivo, although DD1-MMAE showed a trend towards increased necrotic areas.

Conclusions:

  • Anti-EGFR DARPin-based conjugates can be effectively synthesized using a bio-orthogonal conjugation strategy.
  • While exhibiting potent in vitro cytotoxicity, the in vivo anti-tumor efficacy of these conjugates was limited.
  • Further optimization is needed to improve tumor targeting and therapeutic outcomes for DARPin-based protein-drug conjugates in EGFR-overexpressing cancers.